Objective. To develop and explore a protocol for using colour duplex sonography (CDS) in the routine care of GCA.
Introduction
The gold standard for diagnosing GCA is still represented by temporal artery biopsy (TAB); however, TAB is an invasive procedure, and although highly specific it lacks adequate sensitivity and can yield false-negative results in up to 60% of cases [1, 2] .
Efforts have been directed towards finding more accessible, rapid and repeatable diagnostic tools. Colour duplex sonography (CDS) of temporal arteries and large vessels is a diagnostic modality for GCA [3] . US can identify the presence of vessel wall oedema, known as a halo, throughout the length of the vessel, potentially overcoming the problem of skip lesions affecting histological results [4] . Nevertheless, CDS use is still not widespread in routine clinical practice and requires skilled sonographers.
We retrospectively analysed the CDS findings of consecutive patients with suspected GCA examined at our institution in Oxford, providing one of the largest real-life cohorts of patients with GCA assessed using CDS. The aim of this paper was to provide evidence for the application of a standardized CDS methodology in the routine clinical assessment of patients with suspected large vessel vasculitis (LVV) and to explore its role in follow-up.
Methods
Patients with suspected GCA were referred from general practitioners or other Departments to the fast-track outpatient clinic of the Rheumatology Department, University of Oxford, between July 2014 and September 2016. The weekly fast-track service provides a preferential booking list dedicated to assessing newly referred patients with suspected GCA, both clinically (by expert rheumatologists) and ultrasonographically (by ultrasonographers experienced in assessing LVV). The ultrasonographer was blinded to the full clinical history, but the CDS result was communicated to the assessing rheumatologists for a final clinical decision and treatment adjustments. In cases with both negative CDS and TAB, the diagnosis was based on clinical presentation, laboratory results, response to treatment and, when available, other imaging modalities (mainly PET-CT). Referring physicians did not delay the initiation of glucocorticoid (GC) therapy prior to assessment. Following initial referral, if the diagnosis was confirmed, patients were followed-up at regular intervals according to clinical necessity. Additional assessments were performed for suspected flares. Flares were defined as the new onset or relapse of symptoms and/or an increase in inflammatory markers not otherwise explained. Patients with established GCA, attending for routine follow-up, were also included. Patients were assessed by a rheumatologist and underwent CDS of both temporal arteries and axillary arteries (AXs) at each visit. The cohort was assessed with the same methodology throughout the period of observation; however, we divided it into an historical cohort (1 July 2014 to 31 December 2015) and a recent cohort (1 March 2016 to 1 September 2016). The two cohorts differed in terms of referrals rate, which increased substantially once the CDS fast-track clinic became integrated into routine clinical practice. In addition, for the recent cohort we collected more details of symptoms, outcome and more specific CDS findings. Data are presented as overall cohort findings and according to visit time-points. Uncertain CDS results were analysed separately.
Ultrasonographic assessment of the arteries Throughout the period of observation, CDS was performed by three rheumatologists (C.B.P., A.F. and S.M.) and a research radiographer (C.P.). All assessors had a period of scanning overlap to ensure that they applied the same methodology [5, 6] . Examination of the superficial temporal arteries (common, frontal and parietal branches) and the AXs in longitudinal and transverse planes was performed using a GE Healthcare LOGIQ-E9 machine. A wide-band high-frequency (L8-i18 MHz) linear hockey stick transducer was used for the temporal arteries, and a broad spectrum linear matrix array transducer (ML615 MHz) for the AXs. A Doppler frequency of 10 MHz (56.5 MHz) was applied. Additional settings included: focus 5 mm below the skin surface for temporal arteries, and 3 cm for AXs; depth was adjusted according to the patient's characteristics; dynamic range 4060 dB, B-mode gain between 35 and 45 dB; colour doppler (CD) settings included a pulse repetition frequency of 2.53.5 kHz for temporal arteries, and of 34 kHz for AXs. A low wall filter was selected to detect low-velocity flow. Frame rates were kept high to capture rapid changes in flow dynamics (20) . The colour box was adjusted to obtain an angle steer correction of 460 between sound waves and artery.
The presence of homogeneous concentric or eccentric vessel wall thickening (halo sign) in both transverse and longitudinal views was considered as a positive CDS. The compression sign was applied in transverse views to confirm the findings [7] . Halo thickness was measured in longitudinal planes at the site with the largest diameter. The CDS findings were saved as anonymized images and recorded on a database after obtaining the patients' written informed consent. The sensitivity and specificity of the CDS were tested using clinical diagnosis by an expert rheumatologist as a reference standard. This study was approved by the NRES Committee South Central-Oxford C (REC n. 12/SC/0622).
Statistical analysis
For comparisons between groups, the independent samples t test was used for continuous variables and the Chisquare test for categorical variables. P values < 0.05 were considered significant.
Results
Over a period of 23 months, 377 CDS scans were performed on 293 patients with suspected or established GCA. There was a significant increase in the number of CDSs performed as part of routine care when comparing the historic cohort (206 examinations-a rate of 12/month) with the recent cohort (174 examinations-a rate of 29/ month). The whole cohort consisted of 121 (41%) cranial GCA and 73 large-vessel GCA (25%); a diagnosis of GCA was excluded in 99 patients (34%).
A total of 210 scans (56%) were performed on patients referred for suspected GCA: 89 (24%) were regular followup GCA patients attending routine appointments, and 78 (20%) were established GCA patients with a suspicion of flare. A flow-chart of included patients is shown in supplementary Fig. S1 , available at Rheumatology Online.
Presenting symptoms and laboratory findings
The presenting symptoms at disease onset in the overall population are shown in Table 1 , with headache representing the first symptom in 77% of patients, followed by visual symptoms, jaw claudication or scalp tenderness. For initial referrals, the median symptom duration was 31 days [interquartile range (IQR): 1467]. Detailed data for clinical features on the day of the US scan was available only for the recent cohort. Eighty-one patients (57%) had at least one symptom related to suspected or confirmed GCA at the time of the scan. Headache was the most frequent (39% for new referrals, 69% suspected flares). Lost or reduced vision was mainly reported in new referrals (5%). Jaw claudication persisting on the day of CDS was an uncommon feature in both new referrals and flares (2% and 5%, respectively). PMR was recorded for 23% of suspected flares.
We recorded the results of inflammatory markers assessed just prior to the scan, often while the patient was receiving GC treatment. Among initial referrals with a positive scan, CRP was raised (>5 mg/l) in 75% and ESR (>15 mm/h) in 70% of patients. During follow-up, these figures dropped to 38% and 28%, respectively. In the case of suspected flare, and a positive CDS, 69% showed an increased CRP and 38% an elevated ESR.
CDS findings, clinical diagnosis and GC treatment
In the overall population, 102 (27%) patients had a halo in at least one segment, another 16 (4%) were classified as uncertain and 257 (67%) had a negative CDS. Of the 210 cases referred for suspected GCA, a diagnosis was clinically confirmed in 118 (56%). Sixty-nine percent of first referrals were receiving high-dose GCs (530 mg/day) for an average of 17 (33) days. CDS was positive in 52 (44%) cases, negative in 58 (49%) and uncertain in 8 (7%). Among initial referrals with a positive CDS, 38 (73%) were receiving high-dose GCs. Only 9 patients had not received GCs around the time of evaluation. Among new referrals with GCA and <7 days of treatment with GCs (n = 55, of whom 34 had confirmed GCA), the sensitivity of CDS was 63.3% (95% CI: 44%, 80%), specificity 100% (95% CI: 83%, 100%), positive predictive value 100% and negative predictive value 64.5% (95% CI: 53%, 74%). Considering only patients who had received 57 days of GCs (n = 137, of whom 75 had GCA), the sensitivity of CDS dropped to 43.6% (95% CI: 32%, 56%), specificity 98.3% (95% CI: 91%, 100%), positive predictive value 96.9% (95% CI: 81%, 99%) and negative predictive value 59.1% (95% CI: 54%, 64%). On the other hand, restricting the analysis to new referrals with jaw claudication and high inflammatory markers (ESR > 50 mm/h and/ or CRP > 40 mg/l) who had received GCs < 7 days (n = 13), the sensitivity rose to 81.8% (95% CI: 48%, 98%), and the specificity remained at 100% (95% CI: 2.5%, 100%).
Sensitivity and specificity did not significantly differ between the historic and the recent cohort.
TAB findings and correlation with CDS
Thirty-one TABs were performed in initial referrals, and a result consistent with GCA was obtained in five cases, providing a sensitivity of 29% (95% CI: 10.3%, 55.9%). The overall number of biopsies dropped from 72 (42%) in the historic cohort to 36 (25%) in the recent cohort (P = 0.002) Table 1 . Nine patients from the historic cohort underwent both CDS and TAB at disease presentation. In four patients both TAB and CDS were compatible with GCA; three (75%) of these patients had a bilateral temporal artery halo, and all of them had at least a common branch of the temporal artery involved at CDS. The other five patients had a positive CDS, with a bilateral halo in 4 (80%), but a negative TAB. Patients from the recent cohort did not undergo a TAB if the CDS was positive. Overall, one patient with suggestive clinical features for GCA had a positive TAB in the presence of a negative CDS, performed at 20 days after GCs initiation. A comparison of clinical presentation, treatment and TAB results for patients with a confirmed diagnosis of GCA with or without a positive CDS, and patients for whom a diagnosis of GCA had been excluded, is shown in Table 2 . Systemic symptoms were significantly more common in GCA/CDSpositive compared with GCA/CDS-negative patients (P = 0.001).
CDS findings during follow-up and flares
During follow-up, CDS was positive in 19 (21%) of 89 routine scans in asymptomatic individuals with established GCA. Of 78 patients assessed for a possible relapse, 29 (37%) had a positive CDS. A clinical relapse was confirmed in 50/78 patients.
Uncertain CDS findings CDS findings were uncertain in 11 (5%) of initial referrals, of whom 8 (67%) had a confirmed clinical diagnosis of GCA. Table 3 shows CDS findings, including uncertain results, stratified by clinical diagnosis certainty and number of days on GCs. Uncertain CDS findings were found in both diagnostic and treatment groups, without significant differences. An uncertain CDS result was recorded for 3 (3.4%) patients in the follow-up group, and 2 (2.5%) in the flaring one.
Specific CDS findings
Among patients with a positive CDS, exclusive temporal artery involvement (of at least one branch) was detected in 74% of cases, 11% had exclusive AX involvement, while 15% had concomitant temporal artery and AX involvement. Halos were bilateral in 54% of temporal arteries and 56% of AXs. The distribution of the sites with a halo is presented in Table 4 . The left superficial temporal artery was the most commonly affected site (75%). Figure 1 shows the distribution of the number of sites with a halo according to visit time-point. The percentage of patients with just one site showing a halo was significantly lower in new onset patients (9%) compared with in follow-up (47%; P = 0.001) or flaring patients (31%; P = 0.02). Only new or flaring patients displayed a higher number of sites with halos ( Fig. 1) : 21 (39%) of initial referrals had 54 sites, compared with 2 (7.7%) of flaring patients (P = 0.008) and none of follow-up patients (P = 0.003). Details on the halo size according to the different timepoints were available for the recent cohort and are shown in Table 5 . Taking into account the small number of patients, there were no significant differences in the thickness of temporal artery halos. Therefore, in case of flares, halo thicknesses were comparable with those detected at disease onset. The halo thickness of AXs significantly reduced from initial referral to follow-up, and flares [average thickness from 1.6 (0.4) mm to 1.4 (0.2) in follow-up patients, P = 0.01; and 1.4 (0.2) in patients experiencing flares, P = 0.02].
Other concomitant treatment and outcomes Data on immunosuppressants and outcomes were only available for the recent cohort. Concomitant immunosuppressants together with GCs were given to 11 (13%) patients assessed for suspected GCA, 12 (25%) follow-up patients and 5 (13%) with a flare. MTX was the most common immunosuppressant, prescribed to 23 patients. Other agents prescribed were LEF (two patients), AZA (one patient) and MMF (one patient). Of the patients in the recent cohort, 71 (41%) were receiving anti-aggregants. Overall, permanent visual loss affected 14 patients (10%) from the recent cohort, one with bilateral blindness. Of these 14 patients, 8 were first referrals who had visual loss as the presenting symptom of GCA. Only one patient (0.7%) became blind due to a major flare. Two patients (1.4%) had an ischaemic cerebrovascular event.
Clinical characteristics of patients without a confirmed diagnosis of GCA In 99 subjects a diagnosis of GCA was not confirmed; 92 cases were new referrals. Of these, CDS was positive the temporal arteries in two patients (4%), and uncertain in three. The two patients with a positive scan had a previous diagnosis of PMR and presented with a flare of PMR symptoms. One of them had associated jaw pain. Nevertheless, the overall clinical presentation was not judged to be convincing for GCA by the treating clinicians. One of the uncertain cases had a negative TAB.
Discussion
CDS is a diagnostic tool for GCA supported by increasing robust evidence [811] . Nevertheless, it is still not widely used in routine practice, it requires skilled sonographers (being highly operator-dependent), and its role in followup is still incompletely understood. Our study demonstrates the advantages and pitfalls for real-life assessment of patients with suspected GCA with routine CDS following a standardized methodology as previously described [6] . This study provides one of the largest real-life cohorts of patients assessed with CDS [12] .
We demonstrated that 44% of the patients with confirmed GCA (56% of the patients referred from primary care) had a positive scan. Among new referrals treated with GCs for <7 days, the sensitivity of CDS was 63.3% (95% CI: 44%, 80%), with a high specificity of 100% (95% CI: 83%, 100%); however, among patients who had been treated with >7 days of GCs, sensitivity dropped to 43.6% (95% CI: 32%, 56%), while specificity remained high: 98.3% (95% CI: 91%, 100%).
The sensitivity of CDS in our cohort was lower compared with that in a number of previously published reports [8, 13] . Nevertheless, for the group assessed early after GCs commencement, data were comparable with those of the TABUL study [14] , a large international multicentric prospective study applying the same methodology. The significant reduction in sensitivity for patients treated with GCs for 57 days highlights the importance of implementing fast-track services in everyday practice.
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TABLE 2 Comparison of clinical characteristics among initial referrals according to diagnosis and US findings
(A) Positive CDS and GCA, n (%) (n = 52) (B) Negative CDS but GCA, n (%) (n = 58) (C) Negative CDS and NOT GCA, n (%) (n = 92) P-value
Glucocorticoid treatment
Not on GCs on day of CDS 9 (17) 8 (14) 22 (23) In our cohort, 69% of initial referrals were receiving highdose GCs for an average of 17 (33) days; only nine patients had not received treatment in proximity to the scan. The timing for resolution of CDS findings in response to GC treatment is still unclear, with previous reports ranging from 2 days [15] to several weeks [16] . Hauenstein and colleagues [17] evaluated the impact of the duration of initial GC treatment on CDS findings, demonstrating that the sensitivity of CDS for detection of GCA rapidly decreases with treatment (ranging from 85% within the first day of GCS, to 50% within 24 days or >4 days from GCs initiation). Another explanation for the relatively low sensitivity is that symptoms duration, despite fast-track assessment, was prolonged (median 31 days, IQR: 1467), mainly due to a delay in the recognition of the clinical features and therefore referral from primary care. Moreover, ultrasonographers were blinded to the full clinical history of the patient, and uncertain CDS findings could have been interpreted differently if influenced by the clinical presentation. The natural learning curve [14] and the increasing expertise gained by ultrasonographers during the period of observation might have also influenced early US results. If we were to consider the uncertain CDS results as positive scans in those patients with a final clinical diagnosis of GCA, our sensitivity would have raised to 68% (95% CI: 49.5%, 82.6%). Nevertheless, when restricting the analysis to patients with a high pretest probability for GCA, namely new referrals with jaw claudication and high inflammatory markers who had received GCs for <7 days, the sensitivity reached 81.8% (95% C:I 48%, 98%) and specificity 100% (95% CI: 2.5%, 100%). The very high positive predictive value in our cohort confirms the hypothesis that CDS, if performed by trained sonographers, can be used to confirm a diagnosis of GCA with sufficient confidence to avoid TAB in selected patients [18] . In the small number of patients who underwent both TAB and CDS, most cases with histology consistent with GCA also had bilateral halos, and almost invariably the common branch of the temporal artery was involved; this is consistent with previous reports highlighting the value of a bilateral halo in increasing the specificity of CDS up to 100% [4, 8, 9] . Only one case had a positive TAB but a negative CDS.
The rate of CDS performed as part of everyday clinical practice in Oxford significantly increased over the last 2 years, with an increase in the average monthly scans from 12 to 29/month; corresponding to a reduction in the rate of TABs performed from 72 (42%) in the historic cohort to 36 (25%) in the recent cohort (P = 0.002). The reduction in the number of TABs can be explained by the increasing reliance on finding a positive CDS as constituting sufficient evidence of GCA in patients with a suggestive clinical picture [9, 10, 18] . The majority of our patients had exclusive temporal artery involvement, with the common and frontal branches being the most affected; nevertheless, 15% had concomitant AX involvement and 11% showed exclusive AX involvement, underlining the importance of scanning the AXs. Data on systemic symptoms were available for the recent cohort and were recorded in 11 patients only. This could account for the relatively low percentage of patients with AX involvement, but was also the only significant feature distinguishing GCA/CDS-positive and GCA/CDSnegative patients. There was a trend towards a higher prevalence of treatment with high-dose GCs for a shorter period of time, and higher inflammatory markers and jaw claudication among GCA/CDS-positive patients compared with GCA/ CDS-negative ones. In contrast, all these features were significantly different between GCA/CDS-positive patients and non-GCA subjects.
The role of CDS in the follow-up of patients with GCA, particularly in the detection of disease flares and remission still needs to be defined. In our cohort we recorded a flare rate of 17%. CDS was positive in 37% of patients with a suspected clinical flare, rising to 58% if we only considered 
FIG. 1 Distribution of sites with halo
Proportion of patients with a specific number of sites showing a halo according to the different visit time-points.
www.rheumatology.oxfordjournals.org confirmed flares with treatment adjustments. However, this data might be biased, because CDS could have played a strong role in influencing the clinical decision to identify a real flare. Only 68% of flaring patients with a positive scan had raised inflammatory markers; therefore, CDS could be particularly useful in confirming a flare in patients for whom blood tests fail to detect a relapse [19] .
We demonstrated that the number of sites with halos decreased over follow-up, in keeping with previous reports [16] . Interestingly, only new or flaring patients displayed four or more sites with a halo: 39% of initial referrals, compared with 7.7% of flaring patients (P = 0.008) and none of the follow-up patients (P = 0.003). These data provide evidence that CDS can have an important role in distinguishing between active disease and remission, and that, despite treatment, a disease flare can be detected as effectively and with widespread findings (in terms of number of sites with halo) as in new onset patients.
The analysis of temporal artery halo size showed that, even though there were no significant differences in the average sizes over time, halo sizes comparable with disease onset were recorded during flares, again supporting the potential role of CDS in detecting patients with disease relapses. The halo size of AXs showed a significant decrease during follow-up and flares compared with in first referrals. One of the reasons why we failed to demonstrate a significant difference in the halo size in the temporal arteries over time might relate to the high prevalence of GC use in our population. Data from the TABUL study have demonstrated that the size of the halo was significantly smaller in patients who had received >4 days of high-dose GCs [20] . Halo size in this cohort was similar to the halo size in a recently published cohort from another centre [21] .
Our study has some limitations, including the retrospective nature, the smaller sample size of some of the groups analysed, and some differences in data available between the historic and the recent cohort. Selection bias towards a tertiary centre with a high level of expertise in vasculitis might have influenced the type of population analysed. The delay in referral of patients from primary care and the high prevalence of treated patients might have severely affected our results; however, this probably faithfully reflects real-life clinical practice. Finally, the precise advantage of the fast-track service over the standard practice would be better acknowledged with a prospective, comparative study.
In conclusion, the application of our proposed methodology for the CDS evaluation of patients with suspected Comparison between average size from the newly diagnosed GCA group and the flare group.
GCA, characterized by the routine assessment of both temporal arteries and AX arteries, provides high specificity and positive predictive value for diagnosing active GCA. Moreover, the introduction of CDS in routine care allows for a significant reduction in TAB. Promising evidence on the use of CDS during follow-up and in detecting disease flares has emerged.
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